Agios Stock Gains 18.6% After FDA Approves Anemia Drug Aqvesme

Edgen Stock·Dec 24 2025, 18:04

Share to

Share to

Copy link

Key Takeaways

Agios Pharmaceuticals received FDA approval for its drug Aqvesme to treat anemia in adults with thalassemia, causing its stock to climb significantly. While a major milestone, the drug's sales potential from this indication alone is not expected to make the company profitable, placing focus on future approvals.

Regulatory Win: On December 23, 2025, the U.S. FDA approved Agios' drug Aqvesme for treating anemia in adults with Alpha- or Beta-Thalassemia.
Market Reaction: Following the news, shares of Agios (AGIO) increased 18.63% to close at $29.17, reversing a year of underperformance.
Future Outlook: Analysts project peak sales of $500 million for this indication, but profitability hinges on securing approval for sickle cell disease (SCD).

AGIO Shares Climb 18.6% on Key FDA Approval

Agios Pharmaceuticals (NASDAQ: AGIO) stock increased 18.63% on December 23, 2025, after the U.S. Food and Drug Administration (FDA) approved its drug, Aqvesme (mitapivat). The approval authorizes the drug for treating anemia in adult patients with Alpha- or Beta-Thalassemia, a group of inherited blood disorders. This regulatory milestone provides a significant boost for the company, whose stock had previously fallen 29% over the past year, lagging the broader market by 47%. The approval was granted despite the drug carrying a boxed warning for potential liver injury.

Sales Capped Near $500M as Focus Shifts to Future Trials

While the thalassemia approval is a critical step, its commercial upside is limited. Analysts estimate peak annual sales for Aqvesme in this indication at approximately $500 million, a figure considered insufficient to drive the company to overall profitability on its own. The company's future growth now heavily depends on securing an additional FDA approval for Aqvesme to treat sickle cell disease (SCD), a potentially larger market, despite the drug showing mixed results in its Phase 3 trials for that condition. Agios remains well-capitalized to fund these efforts, holding a strong cash position of $1.3 billion against just $101 million in liabilities. Analysts project the stock could reach $34 per share based on the thalassemia approval alone.